Linder the Panerunds Reduction Act of 1995, no persons are required to a

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor   Wael			10659862	
			2003-09-11	
		Wael	R. Joseph	
	Art Unit		1615	
Examiner Name Hasar Attorney Docket Number		Hasar	n Syed Ahmed	
		er	KCC 4979.2 (K-C 19.378C)	

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue [	Date	Name of Patentee or Applicant of cited Document		Releva	,Columns,Lines when ant Passages or Rele s Appear	
	1	6153209		2000-11	1-28	Vega, et al.				
If you wish	n to a	ı dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant		Releva	Columns,Lines when ant Passages or Rele s Appear	
	1									
If you wish	to a	dd additional U.S. Publi				,		d button	Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>			Kind Code4	Publication	Name of Patente Applicant of cited Document	or '	Pages,Columns,Line where Relevant Passages or Relevan Figures Appear	т
	1									
If you wish	n to a	l dd additional Foreign P	atent Do	cument	citation	information pl	Lease click the Add	button	Add	
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Т				

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Examiner N

Application Number		10659862	
Filing Date		2003-09-11	
First Named Inventor	Wael	R. Joseph	
Art Unit		1615	
Examiner Name	Hasan Syed Ahmed		
Attorney Docket Number		KCC 4979.2 (K-C 19.378C)	

		1	Dow Corning (TM) 5329 Product Literature from www.dowcoming.com				
		2	Dow Coming (TM) 2503 Product Literature from www.dowcoming.com				
If you wish to add additional non-patent literature document citation information please click the Add button Add							

EXAMINER SIGNATURE

Examiner Signature

Date Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through a citation in no conformance and not considered. Include coop of this form with next communication to applicant.

1 See Kind Codes of USPTO Pittent Documents at <u>were USPTO GOT</u> or MPEP 901.04. \* Entire office that issued the document, by the two-letter code (WIPO Standard STS.). \* For Japanese patent documents, the adulation of the year of the eignor of the direction must precise the senior in order of the patent document. Experiment of the patent document. Experiment of the patent document. Experiment processes a substitute on the document users with Senior 45.71 (a) for the patent document. Experiment processes - Applicate this patent senior exists when the patent patent processes are senior exists when the patent paten

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 GFR 1.99)

Application Number			10659862	
	Filing Date		2003-09-11	
First Named Inventor Wael I		Wael	R. Joseph	
Art Unit			1615	
	Examiner Name Hasar		Syed Ahmed	
Attorney Docket Number		er	KCC 4979.2 (K-C 19,378C)	

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97 an	d 1.98 to make the	appropriate selection(s):
---------------	-------------	--------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97 CFF 1.97(e)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

torn of the agriculture.							
Signature	/Christopher M. Goff/	Date (YYYY-MM-DD)	2006-10-20				
Name/Print	Christopher M. Goff	Registration Number	41 785				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.